Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
BreezeBio logo — Genetic Medicine Delivered

BreezeBio

Genetic Medicine Delivered

Founded 2016 United States Brisbane, United States 64 employees Series B Total: $118.50M Biotechnology

General Information

Company Name BreezeBio
Founded Year 2016
Location United States Brisbane, United States +1
Employees 64
Industries Biotechnology
Funding Stage Series B
Social

Get notified when BreezeBio moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

AI Insight

Bounce Watch AI
2 months ago

BreezeBio recently secured a $60M Series B round, fueling its strategic expansion and pipeline progression. This is evidenced by the formation of an inaugural Scientific Advisory Board with a key advisor hire in May 2026, and an upcoming oral presentation at the American Diabetes Association's Scientific Sessions in June 2026 to highlight its lead type 1 diabetes program. These moves collectively underscore the company's advancement towards clinical development and strengthening its scientific leadership.

Signal Types
Funding Hiring Event Product Development
Strategic Labels
Pipeline Advancement Scientific Leadership Growth Funding
Next Move: Clinical Trials
·
Impact: 8/10
·
Ideal For: Biotech VCs – Late Stage / Growth Equity

About BreezeBio

BreezeBio, with the slogan "Genetic Medicine Delivered," is a biotechnology company focused on creating precision genetic medicines. Established in 2016 and situated in the South San Francisco area, the company specializes in non-viral delivery methods for genetic therapies across biologically relevant tissues.

Their proprietary NanoGalaxy® platform is engineered to deliver genetic payloads, like mRNA, to specific cell types. This platform has shown effective delivery to immune cells and several tissues in the heart, lung, and central nervous system. BreezeBio is progressing its internal therapeutic pipeline, targeting autoimmune diseases and oncology, with its flagship program, BRZ-101, advancing towards IND-enabling studies in type 1 diabetes.

Recently, the company secured a $60.00M Series B investment, underscoring investor confidence in its innovative approach and growth potential in the genetic medicine space.

Taxonomy: Precision Medicine, Genetic Medicine, Non-Viral Delivery, NanoGalaxy® Platform, Nanoparticles, mRNA Delivery, Immune Cells, Tissue Specific Delivery, Autoimmune Diseases, Oncology, Type 1 Diabetes, Immune Tolerance, Therapeutic Pipeline, IND-Enabling Studies

Services & Products

Targeted delivery of genetic medicines
Development of immune modulation therapies
Research and development of precision genetic medicine platforms

Target Customers

Healthcare professionals Biopharmaceutical companies Patients with autoimmune diseases Research institutions

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Series B •••••• - 01 Feb 2026
Series A •••••• 18
Investor Investor Investor Investor Investor Investor Investor Investor Investor Investor Investor Investor Investor Investor Investor Investor Investor
•••• •••• 		01 Jan 2024
Series A •••••• 12
Investor Investor Investor Investor Investor Investor Investor Investor Investor Investor Investor
•••• •••• 		01 Sep 2021
Seed •••••• 4
Investor Investor Investor
•••• •••• 		01 Dec 2018
Spinout •••••• 1 •••• •••• 01 Dec 2016

View All 6 Funding Rounds

BreezeBio Alternatives & Competitors

BreezeBio vs
Granza Bio
Granza Bio

Reprogramming Immunity for Target-Specific Medicines

Seed
7 employees
Biopharma, Biotechnology
Compare BreezeBio vs Granza Bio
BreezeBio vs
MiroBio Ltd
MiroBio Ltd United Kingdom

Restoring balance to the immune system to treat disease

Series B
5 employees
Biotechnology, Life Sciences
Compare BreezeBio vs MiroBio Ltd
BreezeBio vs
AusperBio
AusperBio United States

Transforming Patient Lives For a Better Tomorrow

Series B
8 employees
Biopharma, Biotechnology
Compare BreezeBio vs AusperBio

FAQ About BreezeBio

Genetic Medicine Delivered
BreezeBio was founded in 2016.
BreezeBio is headquartered in Brisbane, United States.
BreezeBio operates in the following industries: Biotechnology.
BreezeBio has approximately 64 employees.
BreezeBio has completed 6 funding rounds, raising a total of $118.50M. The latest funding stage is Series B.
BreezeBio offers: Targeted delivery of genetic medicines, Development of immune modulation therapies, Research and development of precision genetic medicine platforms.
Top alternatives and competitors to BreezeBio include Granza Bio, MiroBio Ltd, AusperBio, Nuvig Therapeutics Inc., Locanabio, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
BreezeBio and Granza Bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors BreezeBio and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy